Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed COO
Appointed director
Letter to company
Director departure

Urigen Pharmaceuticals, Inc. (URGP) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/20/2020 D Form D - Notice of Exempt Offering of Securities:
02/07/2018 D Form D - Notice of Exempt Offering of Securities:
04/13/2017 D Form D - Notice of Exempt Offering of Securities
02/11/2015 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
10/04/2013 D/A Form D - Notice of Exempt Offering of Securities [amend]
07/19/2013 D Form D - Notice of Exempt Offering of Securities
10/05/2012 8-K Quarterly results
09/12/2012 8-K Entry into a Material Definitive Agreement
08/10/2012 10-K Annual Report for the period ended June 30, 2010
06/07/2012 8-K Form 8-K - Current report
01/10/2012 8-K Form 8-K - Current report
09/28/2010 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
09/07/2010 8-K Form 8-K - Current report
07/06/2010 8-K Form 8-K - Current report
05/17/2010 10-Q Quarterly Report for the period ended March 31, 2010
05/04/2010 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Amendment dated April 19, 2010by and between Urigen Pharmaceuticals, Inc. and Platinum-Montaur Life Sciences, LLC",
"Certificate of designation of the relative rights and preferencesOf theSeries C Convertible Preferred Stock filed with the Secretary of State of Delaware on April 21, 2010",
"Warrant issued to Platinum-Montaur Life Sciences, LLC",
"Source: Urigen Pharmaceuticals, Inc. On Monday April 26, 2010, 9:25"
04/23/2010 BW Urigen Files Request for FDA Meeting
04/12/2010 BW Presentation by Lowell Parsons, MD Now on Urigen.com
03/22/2010 3 Vickery Dan B (Director) has filed a Form 3 on Urigen Pharmaceuticals, Inc.
03/18/2010 BW Urigen CEO Interview on Urigen.com
03/03/2010 8-K Form 8-K - Current report
03/03/2010 BW Edward R. Teitel, MD, JD Becomes Chairman of Urigen
02/22/2010 BW Lowell Parsons, MD To Make Urigen Presentation in Atlanta
02/17/2010 BW William K. Schmidt, PhD Joins Urigen's SAB
02/16/2010 10-Q Quarterly Report for the period ended December 31, 2009
01/15/2010 8-K Form 8-K - Current report
12/31/2009 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
12/21/2009 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Consulting Agreement between Urigen Pharmaceuticals, Inc. and Oceana Therapeutics",
"Urigen & Oceana Collaborate on FDA Meeting Preparation SAN FRANCISCO, Dec. 21, 2009 -- Urigen Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101. "Oceana has expertise in developing and commercializing drugs which are delivered procedurally, including in urology," said Urigen’s CEO William J. Garner, MD. “This allows Urigen to move URG101 forward with a talented potential partner to prepare for an FDA meeting.” David S. Tierney, M.D., President and COO, Oceana Therapeutics said, “We’re excited about the potential of URG10..."
12/07/2009 8-K Appointed a new director
11/16/2009 10-Q Quarterly Report for the period ended September 30, 2009
10/29/2009 8-K Form 8-K - Current report
10/28/2009 8-K Form 8-K - Current report
10/13/2009 4 Form 4 - Statement of changes in beneficial ownership of securities
09/24/2009 10-K Annual Report for the period ended June 30, 2009
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy